Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
Executive Summary
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
You may also be interested in...
AC Immune CEO Outlines ‘Roadmap’ For Fighting Alzheimer’s
AC Immune’s CEO tells Scrip that treating earlier, targeting Tau, and focusing on more homogeneous populations will be needed to successfully fight Alzheimer’s Disease.
Open-Label Extensions The Key To Gantenerumab Success, Stresses Roche
Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.
AC Immune/Roche Drop Crenezumab After Phase III CREAD Alzheimer's Failure
Interim top-line data from CREAD 1 and 2 indicate crenezeumab is unlikely to meet its primary endpoints and the studies are being stopped, but a clinical study in Colombia in familial Alzheimer’s is set to continue.
Need a specific report? 1000+ reports available
Buy Reports